Syros Pharmaceuticals (SYRS) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Syros Pharmaceuticals (NASDAQ: SYRS) in the last few weeks:

• 4/17/2024 – Syros Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/5/2024 – Syros Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/3/2024 – Syros Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $13.00 price target on the stock.
• 4/1/2024 – Syros Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 3/28/2024 – Syros Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/12/2024 – Syros Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Syros Pharmaceuticals Trading Down 7.6 %

SYRS opened at $4.72 on Friday. Syros Pharmaceuticals, Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $8.17. The firm has a market capitalization of $126.17 million, a PE ratio of -0.82 and a beta of 1.74. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.95 and a quick ratio of 3.95. The company’s 50-day moving average is $6.29 and its 200 day moving average is $5.18.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SYRS. Private Advisor Group LLC purchased a new position in Syros Pharmaceuticals during the first quarter worth about $29,000. Acadian Asset Management LLC purchased a new position in shares of Syros Pharmaceuticals in the 1st quarter worth approximately $97,000. Federated Hermes Inc. grew its holdings in shares of Syros Pharmaceuticals by 45.7% in the first quarter. Federated Hermes Inc. now owns 240,239 shares of the company’s stock valued at $286,000 after acquiring an additional 75,315 shares in the last quarter. XTX Topco Ltd increased its position in shares of Syros Pharmaceuticals by 286.6% during the first quarter. XTX Topco Ltd now owns 44,555 shares of the company’s stock valued at $53,000 after acquiring an additional 33,031 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Syros Pharmaceuticals in the first quarter worth $975,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.